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Comparison of the [35S]mucopolysaccharides ex-
tracted after in vitro incubation of skin biopsy specimens 
from nonlesional and lesional sites of a patient with 
mastocytosis showed that lesional sites incorporated sul-
fate into heparin. After in vitro incorporation of the 
[35S]sulfate, the tissues were extracted sequentially by a 
3-step procedure which utilized high salt concentrations, 
enzymatic digestion and base hydrolysis to liberate es-
sentially all the counts. The extracted pSS]mucopolysac-
charides were separated from free [35S]sulfate, hista-
mine, protein, and hyaluronic acid by ion-exchange chro-
matography utilizing Dowex 1. The pSS]mucopolysac-
charide extracts of the nonlesional skin were completely 
degraded by treatment with chondroitinase ABC, as they 
are predominantly derma tan sulfate with small amounts 
of chondroitin sulfates. The absolute quantity of sulfated 
mucopolysaccharides after Dowex 1 chromatography in 
micrograms of uronic acid per mg wet weight of starting 
tissue was higher in the lesional than the nonlesional 
specimen, while the specific incorporation of [3SS] sulfate 
per microgram of uronic acid was the same. Approxi-
mately one-half of the e5S]mucopolysaccharides ob-
tained in the 3 sequential extracts of lesional tissue was 
resistant to degradation by chondroitinase ABC as de-
termined by gel filtration before and after enzyme treat-
ment, indicating the presence of sulfated mucopolysac-
charides in addition to chondroitin and dermatan sul-
fates. Heparinase treatment of the chondroitinase ABC-
resistant [:JsS]mucopolysaccharides followed by gel fil-
tration revealed an equal distribution of label between 
heparin and heparinase-resistant material presumed to 
be heparan sulfate. Heparin was also directly demon-
strated in extracts oflesional mastocytosis skin by chem-
ical and functional criteria. 
Several lines of evidence suggest that the mast cells of pa-
tien ts with systemjc mastocytosis contain an activity with the 
a nticoagulant properties of heparin. Biopsy of lesional skin sites 
may be followed by a period of prolonged and excessive bleeding 
[1]. Whealing resul ting from the stimulation of a large area of 
body surface of patients with mastocytosis [2,3], flushing follow-
ing the insertion of a nasogastric tube [4], and generalized 
urtication during ampicillin treatment of otitis media [5] have 
been associated with the appearance in the venous blood of an 
anticoagulant activity which was neutralized in vitro by prota-
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mine sulfate. Blood obtained from scraped mastocytosis skin 
lesions has a prolonged clotting time [6], and spontaneous 
bullous lesions appearing in childhood urticaria pigmentosa 
may become hemorrhagic with the tendency to bleed [7]. Ex-
tracts of mastocytoma tissue from dog [8] and mouse [9] possess 
anticoagulant activity, which in the mouse has been further 
characterized as heparin glycosaminoglycan based upon its size 
and charge [10]. The capacity of mouse mastocytoma grown in 
tissue culture to synthesize heparin has been confirmed by 
demonstrating degradation of the sulfated mucopolysaccharide 
products with purified heparinase and not with other muco-
polysaccharidases [11]. 
The demonstration of heparin in dispersed concentrated hu-
man lung mast cells by its physicochemical characteristics, 
susceptibility to degradation by heparinase but not by other 
mucopolysaccharidases, and antithrombin cofactor and binding 
activities [12] prompted a comparable study to demonstrate 
directly the presence of heparin in the lesional s kin of patients 
with mastocytosis. 
MA TERIALS AND METHODS 
Materials 
Whale cartilage chondroitin 4-sulfate, molecular weight 25,000 to 
50,000, shark cartilage chondroitin 6-sulfate, molecular weight 40,000 
to 80,000, porcine skin hyaluronic acid, and chondroitinase ABC from 
Proteus vulgaris (Miles Laboratories, Elkhart, Ind.) ; chymopapain 
from Papaya latex, elastase type I from porcine pancreas, glucurono-
lactone, porcine in testinal heparin, 170 units/mg (Sigma Chemical Co., 
St. Louis, Mo.); Sepharose 4B and Sephadex G-50 (Pharmacia Fine 
Chemicals, Piscataway, N.J.); Dowex l-X2 (100 to 200 mesh, chloride 
form) (Bio Rad Laboratories, Richmond, Calif.); carbazole (Eastman 
Kodak Co., Rochester, N.Y.) ; azure A (Fisher Scientific Co., Fair Lawn, 
N.J.) ; aquasol, carrier-free H235SO" (New England Nuclear, Boston, 
Mass. ); B grade deoxyribonuclease from bovine pancreas (Calbiochem, 
San Diego, Calif.); collagenase (Worthington Biochemical Corp., Free-
hold, N.J.); Eagle's basal medium with Hanks' balanced sal t solution 
(Microbiological Associates, Walkersville, Md.); and penicillin-strepto-
mycin and L-gl~tamine solutions (Grand Island Biological Company, 
Grand Island, N.Y.) were purchased from the manufacturers. Purified 
. heparinase prepared fTom Flavobacterium heparinum was obtained 
from Dr. A. Linker (University of Utah, Salt Lake City, Utah). 
Radioactivity was determined with a liquid scintillation spectrometer 
(Mark III, liquid scintillation system, Seal'le Radiographics Inc., Des 
Plaines, Ill .) with aquasol as the scintillation medium. Counts were 
taken for 10 min and the background, which ranged from 9 to 14 cpm, 
subtracted. Sufficient sample of [35S]mucopolysaccharide was counted 
to yie ld 5 times background. All counts were corrected for the half-l ife 
of 3' S. 
Subject 
After his informed consent was obtained, multiple punch biopsies of 
clinically unaffected and lesional skin sites were taken from a 45 yr-old 
white male with systemic mastocytosis [13] for 5 yr. The mastocytosis 
was manifested as pruritic red-brown papules that urticated with 
trauma, gastrointestinal symptoms that included diarrhea and abdom-
inal pain, and systemic symptoms that included flushing, palpitations, 
syncope, and disorders of cognitive function. Lesional skin sites bled 
for up to 72 hr after punch biopsy while unaffected skin sites were 
unremarkable in this regard. Bleeding time in clinically normal skin 
was 2 min, 30 sec, in contrast to that in lesional skin which was 8 min, 
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45 sec. The prothrombin time and partial thromboplastin times in 
venous blood were within norma l limits. 
Histopathologic Examination 
Skin biopsy specimens were obtained from a skin lesion and a nearby 
clinically normal area after the periphery of both sites at the 4 quad-
rants had been infIltrated with 1% lidocaine without epinephrine. The 
specimen was fixed for 5 hI' in a solution composed of 2% paraformal-
dehyde, 2.5% glu tara ldehyde, and 0.025% CaCh in 0.1 M cacodylate 
buffer, pH 7.4. This fixed tissue was washed in the same buffer, postfD:ed 
in 2% osmium tetroxide, and embedded in Epon; 1-Jlm-thick sections 
were prepru'ed and stained with Giemsa diluted 1:10 in 2% sodium 
borate solu tion, and examined with a ligh t microscope [14,15]' The 
lesional skin site revealed an increase in metachromatically staining 
mast cells (Fig la) which averaged 550 per mm2. Substantial numbers 
of granules are noted outside the ceil , presumably due to the trauma of 
biopsy. The venule in the involved site shows a thickened homogeneous 
basement membra ne while the venule in uninvolved s kin shows mini-
mal basement membrane alterations (Fig Ib) . 
Labeling and Extmction of Sulfated Mucopolysaccharides 
Each biopsy specimen was cut in to fragments which were suspended 
in 50 ml of Eagle's basal medium wi th Hanks' balanced salt solu tion 
containing 2 mM L-glutamine, 200,000 units penicillin, 200 Jlg strepto-
mycin, and 2.5 mCi of e5S]su lfate. The tissue fragments were incubated 
for 18 hr at 37°C under 5.0% CO2 tension (Hotpack Cru'bon Dioxide 
Incubator, P hiladelphia, P a. ), washed 5 times in Hanks' balanced salt 
solu t ion, suspended in 2 ml of 1 M NaCI, disrup ted by 6 cycles of rapid 
freezing and thawing [16], and sedimented at 400 x g for 10 min at 4°C. 
The supernatant, designated salt-solubilized extract, was stored at 4 °C. 
The tissue fragments were next subjected to a 2-step enzymatic deg-
radation (12] in which they were fU'st exposed to pronase, 2 mg/ ml, 
chymopapain, 0.5 mg/ ml, and DNase, 10 mg/ ml, in a total volume of 2 
ml of Hanks' balanced salt solu tion for 30 min at 22°C and then to 
coilagenase, 1 mg/ ml, elastase, 10 units/ml, and DNase 10 mg/ ml in a 
total volume of 2 ml of Hanks' balanced salt solu tion for 30 min at 
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22°C. The DNase was included empirically to eliminate DNA liberated 
dming extraction and decrease the viscosity of the solu t ion. After each 
exposure to enzymes, the fragments were sedimented at 400 x g for 10 
min at 4°C and the supernatants were removed; the 2 supernatants 
containing the enzyme-solubilized extracts were pooled and stored at 
4°C. The extracted and digested fragments were fina lly suspended in 
2 ml of 0.5 N NaOH at 22°C for 18 hr to degrade the remaining 
[35S]mucopolysaccharides to their component glycosaminoglycans 
(17]. After sedimentation at 400 x g for 10 min at 4°C, the supernatan t 
containing the base-solubilized extract was stored at 4°C. Residual 
nonlesional and lesional biopsy debris remaining after the 3-step ex-
traction procedure were separately placed into 10 ml of scin tillation 
fluid , and the 35S cpm were determined to be less than 50. 
Chamcterization of Extracted f~5 SjMucopolysaccharides 
The salt- , enzyme-, and base-solubilized extracts from nonlesional 
and lesional skin biopsy specimens were individua lly dialyzed against 
40 vol of 1.0 M NaCI for 18 hI' at 4°C a nd each was applied to a 1 x 1.5 
cm column of Dowex 1 equalibrated in 1.0 M NaC!. The columns were 
washed with 6 ml of 1.0 M NaCI, and the ["5S]mucopolysacchru'ides 
were elu ted in a stepwise fash ion with 6 ml of 3.0 M followed by 4.0 M 
NaCI [12,16,18,19]. A sample of t he effluent and one of each eluate were 
assayed fo r protein [20] and 35S. The 3.0 M NaCI eluates were then 
dialyzed against 40 vol of distilled water for 18 hr at 4°C, lyophilized to 
dryness, suspended in 0.5 ml of distilled water, and assayed for monic 
acid [21] and 35S. 
Sepharose 4B gel fil tration was used to determine the size of the 
['J5S]mucopolysacchru'ides in the 3 M NaCI Dowex 1 eluate and to assess 
their susceptibili ty to degradation by chondr oitinase ABC. Each sample 
was applied to a 1 x 60 cm Sepharose 4B column eq uilibrated in 2 M 
NaCI at 22°C. Fractions of 1 ml were collected at a f10w rate of 2.5 ml/ 
hI', and a sample of each frac t ion was assayed for radioactivity. Frac-
tions containing [""S]mucopolysaccharides which filtered with a molec-
ular weight of greater than 6,000 were pooled, dialyzed against 40 vol of 
distil led water for 18 IU', lyophilized to dryness, and suspended with 1 
uni t of chondroitinase ABC in 1 ml of 0.05 M Tris buffer, pH 7.6, made 
FIG 1. Histologic sections of skin biopsies from subject. A, Lesional skin with venule (V) and an increased number of mast cells (arrow). B , 
Uninvolved skin with venule (V) and a normal number of mast ce lls (Giemsa, I-Jlm sections, x600). 
212 METCALFE ET AL 
0.1 M NaCI a nd 0.1% bovine serum albumin [16,22]' After a 90 min 
incubation at 37°C, the reaction mixture was fil te red on Sepharose 4B 
under the pretreatment conditions. 
To determine the relative content of heparin , the chondroitinase 
AB C-resistant [""S]mucopolysaccharides filtering on Sepharose 4B 
wi th a molecular weight of greater than 6,000 were pooled, dia lyzed 
against 40 vol of distilled water for 24 hr, lyophilized to dryness, 
suspended in 0.25 ml of distilled water and subjected to fil tration over 
a 1 x 60 cm Sephadex G-50 column equilibrated in water. The sample 
was fil tered at a fl ow rate of 4.0 ml/hr, and 1.0 ml fractions were 
collected. A sample of each fraction was assayed fo r radioactivity. The 
excluded fractions conta ining all the radioactivity were pooled, lyoph-
ilized, and suspended in 0.1 M Na acetate buffe r, pH 7.0, conta ining 250 
iJ.g purified heparinase [16,23,24]' After incubation for 90 min at 30°C, 
the heparinase-treated samples were fil tered over Sephadex G-50 under 
the pretreatment condi t ions, and each fraction was assayed for radio-
activity. 
Measurement o( Histamine and Hep arin 
Biopsy specimens of 35.11 mg wet weigh t fo r lesional and 19.60 mg 
wet weight fo r nonlesional skin were sequentially extracted in salt , 
enzyme, and base, a nd the supernatant fractions separately chromato-
graphed over Dowex 1 as described for the extraction of C5S]muco-
polysaccharides. T he 1 M NaCl D owex 1 efflu ents were assayed fo r 
histamine by radioenzyme assay [25] and the 3 M NaCl eluates fo r 
heparin by cha nge in adsorbance of ODGIO after formation of a heparin-
azure A metachromatic complex [26,27], and by ant icoagulant activity 
in a partial thromboplastin t ime assay using commercial porcine hep-
a rin as a standard [28]. 
RESULTS 
Extraction of r 5SJMucopolysaccharides from Nonlesional 
and L esional Skin 
Separate skin specimens, obtained from a grossly normal 
area, designated "nonlesional," and from a mastocytosis lesion, 
designated "lesional," were each sequentially extracted in salt, 
enzymes, and base, and each of t he extracts was individua lly 
d U'omatographed over Dowex 1. The 1 M N aCl D owex 1 
efflu ents which are free of sulfated mucopolysacch arides [18,19] 
contained more than 99.9% of th e [:J"S]sulfate and all measur-
able protein [29]. The 3 M N aCI eluate contained e5S]muco-
polysaccharides and no measurable protein [18,19,29] and the 
4 M NaCI eluate was free of both protein and [35S]sulfate. The 
3 M NaCl Dowex 1 eluates from each of the 3 sequential 
extraction procedures were separately dialyzed, lyophilized, 
resuspended in distilled water , and assayed for uronic acid and 
e"S]mucopolysaccharides. Salt, enzyme, and base extracts of 
nonlesional skin con tained 0.11, 0.14, and 0.15 ,...g of uronic acid 
per mg tissue, respectively, and th ose oflesional skin contained 
0.92, 0.85, and 1.44 ,...g of uronic acid per mg tissue, respectively 
(Table I). Specific activi ty of [35S]mucopolysaccharides ranged 
from 9 to 12 cpm per mg wet weight nonlesional skin tissue and 
29 to 69 cpm per mg wet weight lesional skin tissue. The specific 
activity per ,...g uronic acid of incorporated [:J"S]sulfate was 
similar in nonlesional and lesional extracts, being 37 to 41 cpm/ 
TABLE 1. Uronic acid and r35Sj sul(ate in mucopolysaccharides 
present in the 3 M NaCl Dowex 1 eluates (rom salt., enzym e, and 
base exlracts o( nonlesional and lesional shin (rom a p atient with 
m astocytosis 
Uronic acid [""S]mllcopolysac- Specific activity 
Ilg/ mg" charides cpm/ mg cpm/ mg 
Nonlesional skin 
Salt 0.11 10 40 
E nzyme 0.14 9 37 
Base 0.15 12 41 
Lesional skin 
Salt 0.92 44 48 
Enzyme 0.85 29 34 
Base 1.44 69 48 
" Data expressed per mg wet weight. Nonlesional tissue weighed 
47.47 mg, and t he lesional t issue weighed 61.01 mg. 
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FI G 2. Sepharose 4B gel ftItra t ion of [:J5S]mucopolysaccharides from 
pooled 3 M NaCI Dowex 1 eluates of salt, enzyme, and base extracts of 
nonlesional skin before (upper p anel) and afte r (lower panel) degra-
dation by chondroitinase ABC. Approximately 80% of the [''''S]muco-
polysaccharides in the stippled area of the upper panel was treated 
wi th chondroit inase ABC, which under ident ical conditions completely 
degraded a mixture of 250 iJ.g each of chondroit in 4-sulfate, dennatan 
sulfate, and chqndroi tin 6-sulfate. The locations are marked of chon-
droitin 6-sulfate, average molecular weight 60,000, commercia l heparin , 
average molecular weigh t 12,000, and phenol red, which were ftI tered 
separately over the same column. Blue dextran appeared in fraction 12 
and is no t shown. 
,...g uronic acid in the former and 34 to 48 cpm/ ,...g uronic acid in 
the latter . Because the quantity of C5S]mucopolysaccharides in 
each of the extracts from normal skin was limited , t he 3 extracts 
from normal skin were pooled before subsequent characteriza-
tion, while t he 3 extracts from mastocytosis skin were each 
characterized separa tely. 
Iden tification of Extracted r35SjMucopolysaccharides 
[ J5S]Mucopolysaccharides from pooled nonlesional skin ex-
trac ts filtered over Sepharose 4B in a dispersed pattern (Fig 2, 
upper panel) , and the ma terial filtering in fractions 18 to 30 
containing C"S]mucopolysaccharides of greater t han approx i ~ 
mately 6,000 molecular weight, were pooled, treated with chon-
droitinase ABC, and filtered again over Sepharose 4B. After 
-i 
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treatment with chondroitinase ABC, all CSS]mucopolysaccha-
rides from nonlesional skin appeared between £I'actions 30 to 
38, indicating complete degradation (Fig 2, lower panel) . The 
degradation of C5S]mucopolysaccharides ranging in size from 
approximately 6,000 to 200,000 molecular weight to fragments 
of less than 6,000 molecular weight by chondroitinase ABC 
indicates that all material of appreciable size in nonlesional skin 
was dermatan and chondroitin sulfates. 
The C5S]mucopolysaccharides in the 3 M NaCI Dowex 1 
eluates sequentially extracted from lesional skin by salt, en-
zyme, and base flltered over Sepharose 4B with a pattern 
reflecting a progressive reduction in the size of the C5S ]muco-
polysaccharides (Fig 3, upper panels). The rJ5S]mucopolysac-
charides extracted in salt, which could be expected to contain 
proteoglycan [16,29], flltered with an initial peak that had an 
average molecular weight of approximately 60,000, and a second 
peak consisting of materials of less than 6,000 molecular weight 
(Fig 3, salt, upper panel) . Enzyme-extracted [J5S]mucopolysac-
charides which have been released by digestion of the peptide 
core [30] flltered in 2 peaks. The first peak had an average 
molecular weight of 40,000 with a shoulder of 20,000 average 
molecular weight, and the second peak consisted of molecules 
of less than 6,000 molecular weight (Fig 3, enzyme, upper 
panel). The [3sS]mucopolysaccharides extracted in base which 
cleaves glycosaminoglycan side chains from the peptide core 
[17] fIltered with a single peak of average molecular weight 
20,000 with a small shoulder of low molecular weight materials 
(Fig 3, base, upper panel). Fractions 18 to 30 which contained 
CSS]mucopolysaccharides of greater than 6,000 molecular 
weight were pooled from each of the Sepharose 4B columns, 
treated with chondroitinase ABC, and refIltered over Sepharose 
4B. In each case, approximately one-half of the material which 
had flltered with molecular weight of greater than 6,000 was 
degraded with chondroitinase ABC to material of less than 
6,000 molecular weight. The chondroitinase ABC-resistant ma-
terial in each case filtered with an average peak molecular 
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FIG 3. Sepharose 4B gel flJ.tration of [35S]mucopolysaccharides in 
the 3 M NaC) Dowex 1 eluates from salt, enzyme, or base extracts of 
lesional skin before (upper panels) and after (lower panels) degradation 
by chondroitinase ABC. Approximately 80% of the [35S]mucopolysac-
charides in each of the stippled areas of the upper panels was separately 
treated with chondroitinase ABC, which under identical conditions 
completely degraded a mixture of 250 p.g each of chondroitin 4-sulfate, 
derma tan sulfate, and chondroitin 6-sulfate. The locations are marked 
of chondroitin 6-suLfate, commercial heparin, and phenol red which 
were filtered separately over the same column. Blue dextran appeared 
in fraction 12 and is not shown. 
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FIG 4. Sephadex G-50 gel filtra tion of pooled Sepharose 4B fractions 
of chondroitinase ABC resistant ["5S]mucopolysaccharides in salt, en-
zyme, or base extracts of lesional skin before (upper panels) and after 
(lower panels) degradation by purified heparinase. Approximately 60% 
of the ["5S]mucopolysaccharides in each of the upper panels was 
separately treated with purified heparinase, which under identical 
conditions completely degraded 1 mg of commercial heparin. The 
locations are marked of blue dextran and phenol red, which were 
separately filtered on the same column. 
weight similar to that of the starting material, namely 60,000 
for the salt extract, 40,000 for the enzyme extract, and 20,000 
for the base extract (Fig 3, lower panels). 
The heparin content of the chondroitinase ABC-resistant 
CSS]mucopolysaccharides refiltering on Sepharose 4B with a 
molecular weight of greater than 6,000 was approximated by 
fIltering these fractions over Sephadex G-50 before and after 
treatment with purifIed heparinase. Before treatment with he-
parinase, each extract fIltered in the excluded volume (Fig 4, 
upper panels) , while after heparinase treatment the [35S]mu_ 
copolysaccharides were approximately equally distributed in 
the excluded and included volumes (Fig 4, lower panels). 
The percentages of degradation of the e SS]mucopolysaccha-
rides in the pooled extracts of nonlesional skin and in the 
sequential extracts of lesional skin are summarized in Table II. 
Nonlesional skin [35S]mucopolysaccharides were completely de-
graded by chondroitinase ABC, thereby indicating the presence 
of derma tan and chondroitin sulfates, while lesional skin ex-
tracts were 41.1 to 51.6% degraded by chondroitinase ABC. As 
only 47.6 to 52.4% of the chonchoitinase ABC-resistant 
C5S]mucopolysaccharides were degraded by heparinase, the 
lesional skin contains not only heparin but also probably he-
paran sulfate. 
Direct Measurement of Histamine and Heparin Content in 
Extracts 
Total histamine recovered in the 1 M NaCI effluents from 
salt, enzyme, and base extracts of nonlesional and lesional skin 
was respectively 19.6 and 281.0 ng per mg wet weight. Heparin 
was not detected in the 3 M NaCI eluates of extracts of nonle-
sional skin. Total heparin in the 3 M NaCI eluates from salt, 
enzyme, and base extracts of lesional skin was 0.68 tJ.g per mg 
wet weight by azure A metachromasia, and 0.77 tJ.g per mg wet 
weight by anticoagulant activity. 
DISCUSSION 
A comparison of the C5S]mucopolysaccharides extracted 
after in vitro incubation of skin biopsy specimens from nonle-
sional and lesional sites from a patient with mastocytosis re-
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TABLE II. Percent of [ 3'Sjmucopolysaccharides in nonlesional or lesional shin extracts degraded by selective p olysaccharida.ses 
Extract % of tota l [''''S]mucopolysaccha rid es de- % of chondroitinase ABC-resistant ["' S]muco- % of [,,"S]heparin in total [" 'S]mucopolysaccharides graded by chondroitinase ABC polysaccharides degraded by heparinase 
Nonlesional skin 
Pooled salt, enzyme, and base 
Lesional skin 
Salt 
Enzyme 
Base 
100 
41.1 
50.6 
51.6 
vealed that lesional sites incorporated sulfate into heparin while 
nonlesional t issue did not. After in vitro incorporation of the 
C"S]sulfate, t he tissues were extracted sequentially by a 3-step 
procedUl"e which utilized high salt concentrations to solubilize 
proteoglycan [16,29], enzymatic digestion of the peptide core to 
release fractions of proteoglycan [30], and base hydrolysis to 
cleave glycosaminoglycan side cha ins from the peptide core 
[17,29]. The finding that high salt concentrations extracted 
approximately one-fourth of the C"S]mucopolysaccharides of 
the nonlesional site (Table I) is compatible with earlier obser-
vations that this procedure extracted 29 to 51% of dermatan 
sulfate under condi tions in which a pproximately 80% of the 
hyaluronic acid was extracted from the same normal skin [31]. 
The remaining C"S]mucopolysaccharides were extracted from 
the nonlesional site in essentially equal quantities by sequential 
enzymatic digestion and base. hydrolysis; the sequentially di-
gested fragments had essentially no detectable residual counts. 
The pooled e5S]mucopolysaccharides in extracts of t he nonle-
sional site were completely degraded by treatment with chon-
dl"o it inase ABC (Fig 2), a find ing consistent with previous 
observations that t he sulfated mucopolysaccharides of normal 
human skin are predominantly dermatan sulfates with small 
amounts of ch ondroitin 4-sulfate and chondroitin 6-sulfate [31-
34]. Keratan sulfate is not present in human skin [33]. The 
single instance in which h eparin was identified in normal human 
skin based upon the electrophoretic mobility of toluidine blue 
staining mucopolysaccharides [34] did not exclude the more 
likely interpretation that t he material was derma tan sulfate 
[35,36]. Thus, al though normal skin contains 7,000 to 12,000 
mast cells/mm;] [37,38], previous approaches as well as that 
used in this study have not permitted t he detection of hepar in 
because the amount is small on an absolu te basis relative to 
derma tan sulfate. 
Because lesional sites in patients with mastocytosis contain 
200,000 to 600,000 mast cells/mm;] [37], it has been assumed 
that the anticoagulant activity in blood obtained by scraping 
lesional mastocytosis skin [6] Qr released into the circulation by 
cuta neous, gastrointestinal or infectious stimuli [2-5] represents 
heparin. This assumption is compatible with t he finding that 
protamine sulfate added in vitro neutralized the anticoagulant 
activity in plasma obtained after such stimuli . However, when 
present in sufficient quantities, sulfated mucopolysaccharides . 
other tha n heparin may have anticoagulant activity [39] which 
cou ld logically be expected to be neutralized by a molecule of 
opposite charge. T he absolu te amount of sulfated mucopoly-
saccharides defined by elution in 3 M NaCI from Dowex 1 and 
qua ntified by micrograms of uronic acid per mg wet tissue was 
higher in the lesional biopsy specimen than in the nonlesional 
biopsy (Table I). Mouse mastocytoma cells in culture synthesize 
appreciable amounts of [35S]mucopolysaccharides other than 
heparin [11]. 
Although the incorporation of ['J5S]sulfate per microgram of 
uronic acid in t he sulfated mucopolysaccharides was the same 
for lesional and nonlesional t issues (Table I) , the products 
obta ined from the lesional t issue were not limited to derma tan 
sulfate and chondl"o iti n sulfa te. Only one-half of the ['I5S]mu-
copolysaccharides of greater than 6,000 molecular weight ob-
tained with salt, enzyme, or base extraction, respectively, were 
degraded by chondroitinase ABC (Fig 3). The chondroitinase 
ABC-resistant C"S]mucopolysaccharides of greater than 6,000 
52.4 
51.0 
47.6 
o 
31 
25 
23 
molecular weight in each of the 3 extracts were approximately 
one-half h eparin as revealed by degradation with pUl"ified he-
parinase (Fig 4). The [;]"S]mucopolysaccharide resistant to both 
chondroitinase ABC and heparinase is most likely heparan 
sulfate, which is present on cell surfaces [40]. Keratan sulfate 
has not been found in skin [33] and is prominent in avascular 
tissues [40]. 
Extraction in salt is the only one of the sequential procedUJ'es 
which would have preserved the proteoglycan structure [16,29] 
and it is noteworthy that the chondroitinase ABC-degradable 
materials which would be chondroitin and dermatan sulfates as 
well as the resistant materials, heparin and heparan sulfate, 
have the same average molecular weigh t of 60,000 with a range 
up to approximately 200,000 (Fig 3). The glycosaminoglycan 
side cha ins, which would be t he major component obtained by 
base solubilization [16,17,29], exhibited an average molecular 
weight of 20,000 for both chondroitinase ABC-degradable and 
chondroitinase ABC-resistant e "S]mucopolysaccharides (Fig 
3). A size of 20,000 for the glycosaminoglycan side chains was 
previously recognized for chondroitinase ABC-degradable sul-
fated mucopolysaccharides obtained in human lung fragments 
and for h eparin isolated from dispersed concentrated human 
lung mast cells [12]. 
The theoretical mast cell content of heparin and histamine 
may be calculated by assuming that 550 mast cells per mm2 in 
a 1-flm-thick section represents 5.5 X 105 mast cells per mm3, 
and that a cubic millimeter of t issue has a wet weight of I mg. 
The quantity of heparin per milligram wet weight was 0.68 /lg 
by aZUl"e A metachromasia and 0.77 flg by functional assess-
ment. Different biopsy specimens from the same patient with 
a uronic acid content of 196 flg were estimated to have approx-
imately 2.5~ f;g of heparin per m~igram wet weig~t b~ assuming 
26% of the C"S]mucopolysacchandes were hepann (Fig 4, Table 
II) and that approximately one-third t he weight of h eparin is 
uronic acid . Thus, there is 1.2 to 4.5 flg heparin per lOB lesional 
mast cells, which is similar to the heparin content of dispersed 
human lung mast cells, 2.4 to 7.8 /lg per lOB mast cells [12]. The 
histamine content per 10(; mast cells in lesional skin was 0.51 
flg, while in isolated lung histamine has been reported from 1.0 
to 2.8 flg per lOG mast cells [12,41]. 
The authors would li ke to thank Ms. Jud ith Li tvin, Ms. Ann Hein, 
and Ms. Cindy Tarng for their excellent technical assistance. 
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